Hydrastis Canadensis Whole

Dosage for Hydrastis Canadensis Whole is highly individualized and must be determined by an allergy specialist (allergist). There is no 'standard' dose because the concentration of non-standardized extracts can vary between manufacturers.

Diagnostic Testing Dosage

• Skin Prick Test (SPT): Usually, one drop of a 1:10 or 1:20 w/v glycerinated extract is applied to the forearm or back. A sterile lancet is used to prick the skin through the drop.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, a 1:100 or 1:1000 w/v aqueous dilution may be injected (0.02 to 0.05 mL) to create a small bleb (bubble) under the skin.

Immunotherapy Dosage

• Build-up Phase: Injections typically start at a very low dose (e.g., 0.05 mL of a 1:100,000 dilution) and increase weekly or bi-weekly based on the patient's tolerance.
• Maintenance Phase: Once the 'top dose' is reached (often 0.5 mL of a 1:100 or 1:10 w/v concentration), the interval between injections is increased to every 2 to 4 weeks.

Hydrastis Canadensis Whole is not specifically FDA-approved for use in infants. In older children, the dosage for skin testing is generally the same as in adults, although the number of tests performed at one time may be limited to reduce discomfort and the risk of systemic reactions. Immunotherapy in children is typically reserved for those over the age of 5 who can communicate symptoms of a systemic reaction.

Renal Impairment

No specific dosage adjustments are provided for patients with renal impairment, as the systemic absorption of the allergenic proteins is minimal during diagnostic testing. However, caution is advised in patients with severe renal disease who may have altered inflammatory responses.

Hepatic Impairment

While the alkaloids in Hydrastis canadensis are metabolized by the liver, the quantities used in allergenic extracts are generally too low to require adjustment. Nevertheless, patients with end-stage liver disease should be monitored closely for unusual systemic responses.

Elderly Patients

Elderly patients may have reduced skin reactivity (delayed or smaller wheal/flare responses). Clinicians may need to interpret skin test results more conservatively in patients over 65. Furthermore, the risk of cardiovascular complications from a systemic reaction is higher in this population.

This medication is NEVER for self-administration. It must be administered by a healthcare professional in a clinical setting.

• Preparation: The skin site (usually the volar surface of the forearm or the upper back) must be cleaned with alcohol and allowed to dry.
• Timing: Skin tests are read exactly 15 to 20 minutes after application. Reading too early or too late can result in false negatives or false positives.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Freezing must be avoided as it can denature the proteins and render the extract ineffective. Vials should be kept upright and protected from light.

In the context of immunotherapy, a missed dose can disrupt the desensitization process. If a dose is missed by more than one week, the allergist may need to reduce the next dose to ensure safety. If several weeks are missed, the build-up process may need to be restarted from a lower concentration.

An 'overdose' in the context of allergenic extracts refers to the administration of too much antigen, leading to a systemic allergic reaction (anaphylaxis).

• Signs of Overdose: Rapid onset of hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a sudden drop in blood pressure (syncope).
• Emergency Measures: Immediate administration of epinephrine (1:1000) via intramuscular injection, followed by antihistamines, corticosteroids, and IV fluids. Oxygen and airway management may be required.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to use these extracts at home without medical guidance.

The most common side effects associated with Hydrastis Canadensis Whole are localized to the site of administration. These are often expected results of the diagnostic process rather than 'adverse' effects in the traditional sense.

• Local Erythema (Redness): A red, warm area surrounding the test site. This typically fades within 2 to 6 hours.
• Pruritus (Itching): Intense itching at the site of the prick or injection. This is caused by the release of histamine in the skin.
• Wheal Formation: A raised, white or pale bump at the test site. This is a sign of a positive reaction in sensitized individuals.
• Local Swelling: In immunotherapy, a 'local reaction' is defined as swelling larger than a quarter at the injection site. This may be accompanied by tenderness and warmth.

• Delayed Local Reactions: Swelling and redness that appear 6 to 24 hours after the test or injection. These are typically Type IV (cell-mediated) hypersensitivity reactions.
• Fatigue: Some patients report feeling unusually tired or 'washed out' for several hours following allergy testing or immunotherapy.
• Headache: A mild, transient headache may occur following systemic absorption of the extract components.

• Generalized Urticaria (Hives): Hives appearing on parts of the body distant from the injection site.
• Rhinoconjunctivitis: Symptoms of hay fever (sneezing, runny nose, itchy eyes) triggered by the systemic presence of the allergen.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit if the injection was in the upper arm).

> Warning: Stop taking Hydrastis Canadensis Whole and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening, multi-system allergic reaction. It can involve the respiratory, cardiovascular, and gastrointestinal systems simultaneously.
• Angioedema: Severe swelling of the lips, tongue, or throat that can obstruct the airway.
• Bronchospasm: Sudden constriction of the airways, leading to severe wheezing and difficulty breathing.
• Hypotension (Shock): A dangerous drop in blood pressure, often characterized by dizziness, confusion, or loss of consciousness.
• Cyanosis: A bluish tint to the skin or lips, indicating a lack of oxygen in the blood.

There is little evidence to suggest that Hydrastis Canadensis Whole causes long-term organ damage. However, prolonged use of immunotherapy can lead to 'immunological remodeling,' which is the intended therapeutic effect. In rare cases, patients may develop persistent nodules (granulomas) at injection sites if the extract contains aluminum adjuvants.

While Hydrastis Canadensis Whole may not have an individual black box warning, the entire class of allergenic extracts carries a general warning regarding the risk of severe systemic reactions.

FDA Class Warning Summary: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes following administration. These products should only be administered by healthcare providers prepared to manage anaphylaxis. Patients with unstable asthma or those taking beta-blockers may be at increased risk for severe outcomes.

Report any unusual symptoms to your healthcare provider. Even a mild systemic reaction (like a few hives) should be reported, as it may precede a more severe reaction in the future.

Hydrastis Canadensis Whole must only be used by clinicians who are experts in the diagnosis and treatment of allergic diseases. The primary safety concern is the unpredictable nature of allergic responses. A patient who had a mild reaction previously may have a severe reaction upon subsequent exposure.

No specific FDA black box warning exists for Hydrastis Canadensis Whole as a standalone entity, but it is covered under the Allergenic Extracts Class Warning. This warning emphasizes that these products are not interchangeable with other manufacturers' products and that systemic reactions are a constant risk. The warning also notes that the potency of non-standardized extracts is not verified by a standardized bioassay.

• Anaphylaxis Risk: Every administration of Hydrastis Canadensis Whole carries a non-zero risk of anaphylaxis. Facilities must have 'crash carts' containing epinephrine, oxygen, antihistamines, and equipment for endotracheal intubation.
• Asthma Status: Patients with poorly controlled or unstable asthma are at a significantly higher risk for fatal reactions. Testing or immunotherapy should be postponed if the patient is experiencing an asthma flare-up.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine if an emergency occurs. This makes the management of anaphylaxis much more difficult.
• Infection: Administration should be avoided during acute febrile illnesses, as the baseline inflammatory state may increase the risk of a systemic reaction.

• Post-Injection Observation: Patients MUST remain in the clinic for a minimum of 30 minutes after any skin test or immunotherapy injection. Most fatal reactions occur within this window.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after administration to ensure no significant bronchoconstriction has occurred.
• Skin Site Inspection: The administration site should be checked for excessive local swelling before the patient leaves the clinic.

Hydrastis Canadensis Whole does not typically cause sedation. However, if a patient experiences a systemic reaction or receives emergency treatment (like large doses of antihistamines), they should not drive or operate machinery until the symptoms and the effects of the emergency medications have fully resolved.

There are no direct pharmacological interactions between alcohol and Hydrastis Canadensis Whole. However, alcohol can cause vasodilation and may theoretically increase the rate of absorption of the extract or mask the early signs of an allergic reaction (such as flushing). Patients are generally advised to avoid alcohol on the day of allergy testing.

If a patient experiences a severe systemic reaction, the use of the extract should be re-evaluated. In many cases, the concentration must be significantly reduced, or the treatment must be discontinued entirely. There are no 'withdrawal' symptoms associated with stopping allergenic extracts, but the patient's allergic symptoms may return to their baseline levels.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Hydrastis Canadensis Whole.

• Beta-Adrenergic Blockers (Beta-Blockers): While not an absolute contraindication for diagnostic testing, they are often considered a contraindication for immunotherapy. The clinical consequence is that beta-blockers antagonize the effects of epinephrine, which is the primary treatment for life-threatening anaphylaxis. If a patient on a beta-blocker goes into shock, standard doses of epinephrine may fail to restore blood pressure or open the airways.

• ACE Inhibitors: Some evidence suggests that patients taking ACE inhibitors (e.g., lisinopril) may be at higher risk for more severe systemic reactions to allergenic extracts. The mechanism may involve the inhibition of the breakdown of bradykinin, a potent vasodilator.
• MAO Inhibitors (MAOIs): Drugs like phenelzine can potentiate the effects of epinephrine, potentially leading to a hypertensive crisis if epinephrine is needed to treat a reaction.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can increase the cardiovascular response to epinephrine.

• Antihistamines (H1 Blockers): Drugs like loratadine, cetirizine, and diphenhydramine MUST be discontinued for 3 to 7 days before skin testing. These drugs block the H1 receptors in the skin, preventing the 'wheal and flare' reaction and leading to false-negative results.
• H2 Blockers: Medications like famotidine (Pepcid) can also partially suppress skin test reactions and should be discontinued 24 to 48 hours before testing.
• Systemic Corticosteroids: Long-term use of high-dose steroids (e.g., prednisone) can suppress the immune response and reduce the sensitivity of skin tests.
• Topical Steroids: Applying steroid creams to the test site will suppress the local reaction and must be avoided for at least one week.

• Caffeine: High intake of caffeine may slightly increase heart rate and jitteriness, which could be confused with the early stages of a systemic reaction.
• Alcohol: As noted previously, alcohol can increase blood flow to the skin and potentially alter the size of the wheal and flare reaction.

• Goldenseal Supplements: If a patient is taking oral Goldenseal supplements, they may already be sensitized or, conversely, may have a modified response to the extract. Patients should disclose all herbal use.
• St. John's Wort: This herb induces CYP3A4, which could theoretically speed up the metabolism of the alkaloids (berberine) in the extract, though the clinical significance is likely low.

• Skin Tests: The extract itself is used as a 'lab test.' Anything that interferes with the histamine response (like antihistamines) will invalidate the test.
• Total IgE Levels: Immunotherapy may cause a transient rise in total IgE levels followed by a long-term decline.

For each major interaction, the management strategy usually involves a 'washout period' for interfering drugs or a careful risk-benefit analysis by the allergist.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those for blood pressure or depression.

• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) of less than 70% of predicted values or those with frequent exacerbations should not undergo skin testing or immunotherapy. The risk of a fatal bronchospasm is too high.
• Recent Myocardial Infarction (Heart Attack): Within the last 3 to 6 months. The stress of a systemic reaction or the administration of epinephrine could cause another cardiac event.
• Known Previous Anaphylaxis to Hydrastis Canadensis: If a patient has already had a life-threatening reaction to this specific extract, further use is strictly contraindicated.
• Acute Infection: Testing should not be performed during the acute phase of any infection or febrile illness.

• Pregnancy: While not strictly contraindicated, initiating new immunotherapy during pregnancy is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia. Maintenance immunotherapy may be continued if the dose is stable and well-tolerated.
• Autoimmune Diseases: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have altered immune responses that make the results of testing or the safety of immunotherapy unpredictable.
• Malignancy: Patients undergoing active chemotherapy or radiation may have suppressed immune systems, making allergenic extracts less effective or more risky.

Hydrastis Canadensis belongs to the Ranunculaceae (Buttercup) family. Patients who are allergic to other members of this family—such as Coptis (Goldthread), Ranunculus (Buttercup), or Actaea (Black Cohosh)—may show cross-reactivity with Hydrastis Canadensis Whole. Clinicians should be cautious when testing these patients, as they may have a lower threshold for a systemic reaction.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of fainting or heart palpitations, before prescribing or administering Hydrastis Canadensis Whole.

Hydrastis Canadensis Whole is categorized as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm when administered to a pregnant woman. The primary risk to the fetus is maternal anaphylaxis, which can lead to a sudden drop in placental blood flow and oxygenation (fetal hypoxia). Most allergists will not start a new course of immunotherapy in a pregnant patient. If a patient becomes pregnant while on a stable maintenance dose, the treatment may be continued, but the dose is typically not increased until after delivery.

It is not known whether the allergenic proteins or the alkaloids (berberine, hydrastine) from Hydrastis Canadensis Whole are excreted in human milk. Because the systemic absorption of these components is very low during skin testing, the risk to a nursing infant is likely minimal. However, caution should be exercised. If the mother experiences a systemic reaction, the medications used to treat that reaction (such as high-dose antihistamines) may pass into the breast milk and cause sedation in the infant.

Hydrastis Canadensis Whole is generally considered safe for diagnostic skin testing in children, provided it is performed by a specialist. However, the emotional and physical stress of multiple skin pricks must be considered. In children under 5, the diagnosis of allergies is often done via blood tests (In Vitro IgE testing) first to minimize the risk of systemic reactions. Immunotherapy is rarely started in children under the age of 5 due to their inability to clearly communicate the early symptoms of anaphylaxis.

In patients over 65, the skin's reactivity to histamine and allergens decreases. This can lead to smaller wheal sizes, which may be misinterpreted as a negative result. Furthermore, elderly patients are more likely to have underlying cardiovascular disease, making them more vulnerable to the side effects of epinephrine if it is needed for an emergency. A thorough cardiac evaluation is recommended before starting immunotherapy in an older adult.

There are no specific guidelines for the use of Hydrastis Canadensis Whole in patients with renal impairment. Since the extract is used in minute quantities for testing, no significant accumulation of the drug is expected. However, clinicians should monitor for any signs of altered inflammatory response.

Because the liver is responsible for metabolizing the alkaloids found in Hydrastis canadensis, patients with severe hepatic impairment (Child-Pugh Class C) should be monitored. While the amount of alkaloid in an allergenic extract is small, the overall metabolic capacity of the patient may be compromised, potentially prolonging the presence of these compounds in the blood.

> Important: Special populations, particularly pregnant women and the elderly, require individualized medical assessment and a cautious approach to any allergenic extract administration.

Hydrastis Canadensis Whole acts as an antigen that triggers an IgE-mediated immune response. In sensitized individuals, the specific plant proteins in the extract bind to IgE antibodies already present on the surface of mast cells. This binding causes the mast cells to release pre-formed mediators like histamine and newly synthesized mediators like leukotrienes. This process is the hallmark of Type I hypersensitivity. In immunotherapy, the mechanism involves the induction of 'blocking antibodies' (IgG4) and the modulation of T-cell responses to favor immune tolerance over inflammation.

The pharmacodynamic effect of the extract is measured by the size of the skin reaction (wheal and flare). The response is dose-dependent; higher concentrations of the extract will produce larger reactions in sensitized individuals. The onset of action for a skin test is rapid (within minutes), and the effect typically resolves within a few hours. In immunotherapy, the pharmacodynamic effect is a gradual reduction in clinical symptoms (sneezing, wheezing) upon natural exposure to the plant.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Localized for testing) |

| Protein Binding | Variable (Alkaloids ~60-70%) |

| Half-life | 2-6 hours (for alkaloids) |

| Tmax | 15-20 minutes (for skin reaction) |

| Metabolism | Hepatic (CYP3A4, CYP2D6) |

| Excretion | Renal and Fecal |

Hydrastis Canadensis Whole contains several key isoquinoline alkaloids:

• Berberine (C20H18NO4+): A quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids. It is known for its yellow color.
• Hydrastine (C21H21NO6): An alkaloid that acts as a peripheral vasoconstrictor and has been studied for its effects on uterine contraction.
• Canadine: Also known as tetrahydroberberine.

The 'Whole' extract also includes various proteins, polysaccharides, and lipids that serve as the primary allergens.

Hydrastis Canadensis Whole is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the broader therapeutic category of Allergenics, which includes diagnostic antigens and immunotherapy vaccines. It is distinct from standardized extracts, which have established units of potency (such as BAU - Bioequivalent Allergen Units).